Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
US10786507B2 · kind B2 · utility
10Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 17, 2017 |
| Grant date | Sep 29, 2020 |
| Priority date | — |
| Expiry date | Feb 17, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2059
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.